Technical cookies are required for the site to function properly, to be legally compliant and secure. Session cookies only last for the duration of your visit and are deleted from your device when you close your internet browser. Persistent cookies, however, remain and continue functioning on repeat visits.
We does not use any cookie based Analytics or tracking on our websites; see details here.
Personalisation cookies collect information about your website browsing habits and offer you a personalised user experience based on past visits, your location or browser settings. They also allow you to log in to personalised areas and to access third party tools that may be embedded in our website. Some functionality will not work if you don’t accept these cookies.
CMS Russia has advised Gilead Sciences on its localisation agreement with Pharmstandard JSC under which Pharmstandard’s production facilities will be used to manufacture Gilead’s medicines for treating chronic hepatitis С and HIV. This partnership will provide broad access to Gilead’s proprietary innovative methods for treating these diseases to many people in Russia.
Gilead Sciences, Inc. is a research biopharmaceutical company that has been a leading innovator in the area of HIV control for over 30 years. Gilead operates in more than 35 countries around the world.
Pharmstandard is a leading Russian pharmaceutical company. The company's production facilities include five factories located throughout Russia.
The CMS team was led by Counsel Vsevolod Tyupa, an expert in lifesciences. The leading international legal directory Chambers & Partners describes Vsevolod as a well-regarded lawyer advising both domestic and international clients on the localisation of healthcare businesses as well as on distribution, clinical trials and regulatory compliance.